Kalon Biotherapeutics is a private company formed by The Texas A&M University System in the Spring of 2011. It was formed to provide advanced biologics development manufacturing in the newly constructed National Center for Therapeutics Manufacturing (NCTM) building, a state-of-the-art cGMP facility. Kalon enables rapid, cost-effective drug development through a flexible and scalable clinical manufacturing platform with capabilities to support all classes of biological drug products including vaccines, monoclonal antibodies, cellular and gene therapies. Our capabilities include full upstream and downstream processing assets, supporting both microbial and mammalian expression systems. We can scale up to a 2,000L batch size for clinical materials manufacture supporting up to Phase III "run in."